News
CPHRF
9.65
NaN%
--
Weekly Report: what happened at CPHRF last week (0928-1002)?
Weekly Report · 2d ago
Weekly Report: what happened at CPHRF last week (0921-0925)?
Weekly Report · 09/28 09:24
Stifel Nicolaus Reaffirms Their Buy Rating on Cipher Pharmaceuticals (CPHRF)
TipRanks · 09/23 14:15
Cipher Pharmaceuticals: The Low P/E Isn't What It Seems
Seeking Alpha · 09/22 15:59
Cipher Pharmaceuticals Strengthens Board with Appointment of Industry Veteran Rajiv De Silva
TipRanks · 09/21 23:04
Weekly Report: what happened at CPHRF last week (0914-0918)?
Weekly Report · 09/21 09:25
Weekly Report: what happened at CPHRF last week (0907-0911)?
Weekly Report · 09/14 09:26
Weekly Report: what happened at CPHRF last week (0831-0904)?
Weekly Report · 09/07 09:24
Cipher Wins U.S. Court Ruling Upholding Absorica LD Arbitration Award Against Sun Pharma
TipRanks · 09/01 21:47
Weekly Report: what happened at CPHRF last week (0824-0828)?
Weekly Report · 08/31 09:26
Weekly Report: what happened at CPHRF last week (0817-0821)?
Weekly Report · 08/24 09:26
Cipher Pharmaceuticals Balances U.S. Strain With Epuris Strength
TipRanks · 08/23 00:15
Weekly Report: what happened at CPHRF last week (0810-0814)?
Weekly Report · 08/17 09:27
Cipher Pharmaceuticals price target lowered to C$20 from C$22 at Stifel
TipRanks · 08/17 07:18
Stifel Nicolaus Sticks to Its Buy Rating for Cipher Pharmaceuticals (CPHRF)
TipRanks · 08/13 15:46
Cipher Pharmaceuticals Balances Q2 Earnings Dip With Epuris Growth and Strong Balance Sheet
TipRanks · 08/11 21:38
Weekly Report: what happened at CPHRF last week (0803-0807)?
Weekly Report · 08/10 09:25
Weekly Report: what happened at CPHRF last week (0727-0731)?
Weekly Report · 08/03 09:25
Weekly Report: what happened at CPHRF last week (0720-0724)?
Weekly Report · 07/27 09:26
Weekly Report: what happened at CPHRF last week (0713-0717)?
Weekly Report · 07/20 09:25
More
Webull provides a variety of real-time CPHRF stock news. You can receive the latest news about Cipher Phrmctcls through multiple platforms. This information may help you make smarter investment decisions.
About CPHRF
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.